會議議程
講者簡介
2026/5/2 15:10-15:55 Room 國際會議廳
- Keynote Speech
- Huw Morris
- PhD FRCP
-
Professor of Neurology and Neurogenetics, UCL Queen Square Institute of Neurology
E-mail:h.morris@ucl.ac.uk
Executive Summary:
Huw Morris is Professor of Neurology and Neurogenetics, at UCL Queen Square Institute of Neurology, and Honorary Consultant Neurologist at the Royal Free Hospital and the National Hospital, Queen Square, London. His clinical and research training took place at the National Hospital Queen Square, the Mayo Clinic and the Western Pacific island of Guam. He began research in PSP and related disorders as a PSP Association and MRC Clinical Research Fellow in 1997. His main interests are Neurogenetics, Movement Disorders and Dementia. He leads a UK-wide research network in PSP, Corticobasal syndrome and MSA (PROSPECT and EXPRESS) and a UK-wide research project in genetic Parkinson’s (Parkinson’s Families Project). He leads the cohort group for Parkinson’s and Parkinson’s Plus of the Global Parkinson’s Genetics Program (gp2.org). He also studies genetic determinants of progression and variation in Parkinsonian disorders using clinical and brain bank analysis to help to define new treatments.
Huw Morris is Professor of Neurology and Neurogenetics, at UCL Queen Square Institute of Neurology, and Honorary Consultant Neurologist at the Royal Free Hospital and the National Hospital, Queen Square, London. His clinical and research training took place at the National Hospital Queen Square, the Mayo Clinic and the Western Pacific island of Guam. He began research in PSP and related disorders as a PSP Association and MRC Clinical Research Fellow in 1997. His main interests are Neurogenetics, Movement Disorders and Dementia. He leads a UK-wide research network in PSP, Corticobasal syndrome and MSA (PROSPECT and EXPRESS) and a UK-wide research project in genetic Parkinson’s (Parkinson’s Families Project). He leads the cohort group for Parkinson’s and Parkinson’s Plus of the Global Parkinson’s Genetics Program (gp2.org). He also studies genetic determinants of progression and variation in Parkinsonian disorders using clinical and brain bank analysis to help to define new treatments.
Lecture Abstract:
We have made major advances in the understanding the genetics familial and sporadic and sporadic Parkinson's. This process has been accelerated by the Global Parkinson's Genetics Program (gp2.org) and the focus on non-European populations. Our challenge now is to convert this into new disease modifying therapies and to use this information to understand disease heterogeneity and disease mechanisms as part of global collaborative efforts. One important aspect of this is to integrate pathology and biomarker data into this effort to define new insights. I will define current progress, recent discoveries and the road ahead over the next 5 years.
We have made major advances in the understanding the genetics familial and sporadic and sporadic Parkinson's. This process has been accelerated by the Global Parkinson's Genetics Program (gp2.org) and the focus on non-European populations. Our challenge now is to convert this into new disease modifying therapies and to use this information to understand disease heterogeneity and disease mechanisms as part of global collaborative efforts. One important aspect of this is to integrate pathology and biomarker data into this effort to define new insights. I will define current progress, recent discoveries and the road ahead over the next 5 years.
- Katherine P Rankin
- PhD
-
Professor of Neurology, University of California San Francisco
Director, Socioemotional Neuropsychology Research Group, UCSF Fein Memory and Aging Center
E-mail:Kate.Rankin@ucsf.edu
Executive Summary:
Dr. Kate Rankin is a Professor in the University of California San Francisco Department of Neurology, the Global Health Brain Institute, and the Bakar Computational Health Institute, and is the Director of the Socioemotional Neuropsychology Research Group in the UCSF Memory and Aging Center. She specializes in investigating the neuropsychological and neurologic underpinnings of human socioemotional behavior in aging and neurodegenerative disease. Dr. Rankin’s research utilizes quantitative structural and functional brain imaging to examine the neural substrates of socioemotional functions such as empathy, theory of mind, personality, and the comprehension of the social signals for sarcasm and deception. Dr. Rankin developed a battery of socioemotional tests that was adopted across the US by the NIH Alzheimer’s Disease Coordinating Centers to improve diagnostic accuracy for dementia syndromes. She was a coauthor of the international consensus criteria for the diagnosis of frontotemporal dementia and the 2018 international framework for the diagnosis of Alzheimer’s disease, and is a leader in current efforts to establish international criteria for right-temporal predominant FTD syndrome.
Dr. Kate Rankin is a Professor in the University of California San Francisco Department of Neurology, the Global Health Brain Institute, and the Bakar Computational Health Institute, and is the Director of the Socioemotional Neuropsychology Research Group in the UCSF Memory and Aging Center. She specializes in investigating the neuropsychological and neurologic underpinnings of human socioemotional behavior in aging and neurodegenerative disease. Dr. Rankin’s research utilizes quantitative structural and functional brain imaging to examine the neural substrates of socioemotional functions such as empathy, theory of mind, personality, and the comprehension of the social signals for sarcasm and deception. Dr. Rankin developed a battery of socioemotional tests that was adopted across the US by the NIH Alzheimer’s Disease Coordinating Centers to improve diagnostic accuracy for dementia syndromes. She was a coauthor of the international consensus criteria for the diagnosis of frontotemporal dementia and the 2018 international framework for the diagnosis of Alzheimer’s disease, and is a leader in current efforts to establish international criteria for right-temporal predominant FTD syndrome.
Lecture Abstract:
Significant advances in social cognitive neuroscience have provided important insights into the neural circuits underpinning socioemotional behaviors such as empathy, self-awareness, warmth, and reading others’ intentions, and these findings help explain why these behaviors change in neurodegenerative syndromes like behavioral variant frontotemporal dementia. We will examine how the intrinsically connected functional networks for salience and semantic appraisal normally function to support social behavior, and will show how changes to the functioning in these networks leads to behavioral dysfunction in neurologic disease. Understanding how intrinsic networks support various socioemotional functions allows us to develop and validate tests based on the degree to which they directly reflect changes to these networks. We will review neuropsychological tests that can be used in research and clinical settings in the United States to evaluate social cognition in patients with cognitive disorders, including the neuroscientific evidence for how these tests work. We will also discuss international efforts to develop and validate such tests across languages and cultures.
Significant advances in social cognitive neuroscience have provided important insights into the neural circuits underpinning socioemotional behaviors such as empathy, self-awareness, warmth, and reading others’ intentions, and these findings help explain why these behaviors change in neurodegenerative syndromes like behavioral variant frontotemporal dementia. We will examine how the intrinsically connected functional networks for salience and semantic appraisal normally function to support social behavior, and will show how changes to the functioning in these networks leads to behavioral dysfunction in neurologic disease. Understanding how intrinsic networks support various socioemotional functions allows us to develop and validate tests based on the degree to which they directly reflect changes to these networks. We will review neuropsychological tests that can be used in research and clinical settings in the United States to evaluate social cognition in patients with cognitive disorders, including the neuroscientific evidence for how these tests work. We will also discuss international efforts to develop and validate such tests across languages and cultures.

